


Singapore OTC Switching Regulation

Roy Shyng Director, Regulatory Affairs Johnson & Johnson Asia Pacific Pte. Ltd.

10th WSMI AP Regional Conference: Phuket, Thailand, 22 Oct 2014



Source: Pharmaceutical Society of Singapore

http://www.pss.org.sg/know-your-medicines/safe-use-medicines/safe-use-medicines-singapore

Singapore Regulatory Environment



Health Products Regulation Group's mission: **To wisely regulate health products to meet standards of safety, quality and efficacy**

How Health Science Authority (HSA) enhances public access to safe and effective treatment:

- 1. Exemptions for supply of POM without prescription
- 2. Reclassification: Product-specific

(1) Exemptions for supply of POM without prescription

• List of 21 active ingredients: Conditions for exemption:

✓ Dose; Quantity; Labeling; Age restrictions

- Applies to products containing the same active ingredient and of the same strength for similar indication/s which meet the legal requirements for supply by a pharmacist without a prescription, while their legal classification remain as POM.
- Requires patient information leaflets (PILs) for the medicines supplied under this exemption

Active Ingredient	Exemption for supply of POM wo Rx	Effective date
Fexofenadine	As an oral solid prep containing not more than 180mg Indication: For the symptomatic treatment of allergic rhinitis & chronic idiopathic urticaria Max daily dose: 180mg Max supply: 10 tabs Min age: 12 years	1 July 2013

(2) Reclassification: The Basis of Switch Evaluation

Considerations:

- 1. Patient safety, supplied without HCP supervision
- 2. Potential for abuse (Public Healthcare Protection)

'Downward' switches:

- Medicines may be reclassified from POM to P or P to GSL if they have been deemed sufficiently safe for use with reduced or without medical supervision
- Usually triggered by Companies

'Upward' switches:

- Triggered by H S A internal review
- 59 cases from 2011 to 2014 (none in 2002 2010)
- Injectables, anaesthetics, higher risk actives e.g. morphine sulphate, codeine (tablets, cough linctus)

Reclassification eligibility criteria – Downward Switch

✓ The use of the product has been sufficiently extensive;

- The product has been marketed for a period of time sufficient to establish a post-marketing adverse event profile; and,
- ✓ The product's safety profile gives no cause for concern during the marketing period


Based on industry experience: Reclassification status in other countries



Switch Process: Major Variation 2 (MAV-2)

<u>Abridged</u> evaluation route

Timeline (~10 months excluding stop-clock):



Source: Guidance on Medicinal Product Registration in Singapore (Effective 1 April 2011), Appendix 1

Data requirements



Module 1 / Part I :

- Table of Contents
- □ Introduction / Justification & rationale
- PRISM application form
- Product labels
- □ Approved SPC/PI/PIL
- Proof of approval in UK, US, Canada and/or Australia
- □ Registration Status in Other Countries


Module 2 / Part IV: Summary of Clinical Safety

Not required for 'me-too' reclassification

What can the past switches teach us?


'Downward' reclassifications in Singapore (2002 - 2014)

From POM to P From P to GSL




Success Likelihood #1: Patient Safety – Lower risk products

E.g. based on route of administration Case study: 16 switches from P to GSL in 2002 - 2014



Patient safety/ Public Health Safeguard is paramount!




2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014

Success Likelihood #2: Precedence

Products with <u>similar therapeutic area/APIs</u> are likely to have the same forensic classification

Case study: 16 switches from P to GSL in 2002 - 2014



Precedence: 'Me-too' reclassification

Minoxidil (switched from POM to P)



Switches benefit Public Healthcare System and Consumer Self-care



Structured System & Process for Switch

Government Policy:

Encourage public access

- More treatment choices
 - Lowers healthcare costs
- Patient safety remains assured
 & no potential abuse
 - Pressure of Ageing population



Health Products Regulation Group's mission: To wisely regulate health products to meet standards of safety, quality and efficacy

